Patients with one irAE and multiple irAEs, including ir thyroid disorders, demonstrated incrementally improved OS compared to patients with no irAEs in multivariable models adjusting for the ICPi duration, according to a retrospective cohort study in five academic institutions worldwide enrolling 623 patients with stage III/IV NSCLC treated with anti-PD-(L)1 mAbs [78]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.